HeraMED (ASX:HMD) has raised US$2.8 million via placement and SPP
HeraMED Limited (ASX:HMD) has raised funds to accelerate HearCARE’s commercial roll out and progress ongoing research projects.
HeraMED is a medical technology company leading the digital transformation of maternity care with its proprietary telehealth platform. The company offers a platform that utilizes hardware and software to reshape the doctor/patient relationship using its clinically validated in-home fetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, big data and a digital social networking dashboard.
Oaklins’ team in Australia acted as lead manager in this transaction.
Talk to the deal team
Related deals
Sun European Partners has secured financing to support its acquisition of B&H Worldwide
Sun European Partners has raised debt facilities to support its acquisition of B&H Worldwide.
Learn moreEbidco has finalized a voluntary public tender offer for the shares of Eles Semiconductor Equipment
Ebidco S.r.l. has completed a voluntary public tender offer for the shares of Eles Semiconductor Equipment S.p.A.
Learn moreInstituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Learn more